Ladarixin

DB16212InvestigationalSmall molecule

Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Β-Cell Function).

Mechanism: Pharmacologically active on C-X-C chemokine receptor type 1 and C-X-C chemokine receptor type 2
Curator reviewed
Formula / weight: C₁₁H₁₂F₃NO₆S₂ · 375.33 g/mol (avg)

Resolves to

Compound

UNIIDEH7Q6472OCAS849776-05-2ChEMBLCHEMBL189475

Structure

InChIKeyDDLPYOCJHQSVSZ-SSDOTTSWSA-NSMILESC[C@@H](C(=O)NS(C)(=O)=O)C1=CC=C(OS(=O)(=O)C(F)(F)F)C=C1

Targets

P25024CXCR1P25025CXCR2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ladarixin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account